Insider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Buys $404,500.00 in Stock

Prothena logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Major shareholder William Scully bought 50,000 Prothena shares at an average $8.09 each, investing $404,500 and increasing his stake by 5.12% to 1,027,000 shares.
  • Prothena reported a quarterly loss of $0.32 per share, missing the $0.23 loss consensus; revenue of $0.62 million was also well below analysts’ $9.58 million estimate.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $20.00; PRTA shares were trading at $8.36 in the article.
  • MarketBeat previews the top five stocks to own by December 1st.

Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) major shareholder William Scully acquired 50,000 shares of the company's stock in a transaction on Tuesday, November 17th. The stock was acquired at an average price of $8.09 per share, for a total transaction of $404,500.00. Following the purchase, the insider directly owned 1,027,000 shares of the company's stock, valued at approximately $8,308,430. This trade represents a 5.12% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Prothena Trading Up 0.1%

Shares of PRTA traded up $0.01 during mid-day trading on Thursday, reaching $8.36. The company's stock had a trading volume of 296,699 shares, compared to its average volume of 506,926. Prothena Corporation plc has a 1-year low of $7.70 and a 1-year high of $11.80. The business has a 50-day simple moving average of $8.46 and a two-hundred day simple moving average of $9.15. The stock has a market cap of $429.29 million, a P/E ratio of -17.42, a PEG ratio of 4.33 and a beta of -0.20.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.09). Prothena had a negative return on equity of 9.98% and a negative net margin of 45.44%. The business had revenue of $0.62 million for the quarter, compared to analyst estimates of $9.58 million. Research analysts anticipate that Prothena Corporation plc will post 0.06 EPS for the current year.

Analyst Ratings Changes

PRTA has been the topic of several research analyst reports. UBS Group reissued a "buy" rating on shares of Prothena in a report on Friday, July 24th. HC Wainwright began coverage on Prothena in a report on Friday, November 6th. They set a "strong-buy" rating for the company. Weiss Ratings cut Prothena from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, October 29th. Finally, Wall Street Zen downgraded Prothena from a "buy" rating to a "hold" rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $20.00.

View Our Latest Stock Report on PRTA

Institutional Investors Weigh In On Prothena

A number of institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Prothena in the third quarter valued at about $239,000. Chicago Partners Investment Group LLC raised its stake in Prothena by 59.8% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company's stock worth $211,000 after purchasing an additional 9,650 shares in the last quarter. Pinnacle Associates Ltd. raised its stake in Prothena by 6.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 61,507 shares of the biotechnology company's stock worth $515,000 after purchasing an additional 3,589 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Prothena by 179.1% in the 3rd quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 3,660 shares during the period. Finally, Engineers Gate Manager LP bought a new stake in Prothena in the 2nd quarter valued at about $404,000. Institutional investors own 97.08% of the company's stock.

About Prothena

(Get Free Report)

Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company's pipeline has included programs for Parkinson's disease, Alzheimer's disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.

Recommended Stories

Insider Buying and Selling by Quarter for Prothena (NASDAQ:PRTA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prothena Right Now?

Before you consider Prothena, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.

While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines